Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Fmnl1em1flox/Cya
Common Name:
Fmnl1-flox
Product ID:
S-CKO-19153
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Fmnl1-flox
Strain ID
CKOCMP-57778-Fmnl1-B6J-VB
Gene Name
Fmnl1
Product ID
S-CKO-19153
Gene Alias
8030453N10Rik; Fmnl; Fnrl; Frls
Background
C57BL/6JCya
NCBI ID
57778
Modification
Conditional knockout
Chromosome
11
Phenotype
MGI:1888994
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Fmnl1em1flox/Cya mice (Catalog S-CKO-19153) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000042286
NCBI RefSeq
NM_001077698
Target Region
Exon 4~6
Size of Effective Region
~1.9 kb
Detailed Document
Click here to download >>
Overview of Gene Research
Fmnl1, formin-like 1, belongs to the formin family and is responsible for cytoskeletal remodeling, playing a role in various biological processes including cell migration, proliferation, and the immune response [1,2,3,5,6,7,9]. It is involved in multiple signaling pathways such as those related to CXCR2, TGF-β1, and Rac1 [1,3,7].

In cancer, FMNL1 has been extensively studied. In clear cell renal cell carcinoma (ccRCC), its upregulation promotes metastasis via induction of CXCR2, and high expression correlates with advanced tumor stage and poor prognosis [1]. In nasopharyngeal carcinoma (NPC), high FMNL1 expression is associated with aggressive disease, and it enhances cell aggressiveness by epigenetically upregulating MTA1 [2]. In non-small cell lung cancer (NSCLC), reducing FMNL1 expression suppresses cell proliferation, migration, invasion, and bone metastasis by reducing TGF-β1 expression [3]. In leukemia cells, FMNL1 depletion reduces cell proliferation, colony formation, and migration [7]. In glioblastoma multiforme (GBM), FMNL1 is an independent predictor of poor prognosis, and its downregulation suppresses cell migration and invasion [6]. In breast adenocarcinoma, FMNL1 is required for efficient cell migration, and its γ-isoform enhances cell adhesion and migration by bundling filamentous actin [9]. In gastric cancer, elevated FMNL1 is associated with larger tumor size and higher disease stage [10]. Also, FMNL1 is a biomarker for tumor-infiltrating immune cells and is associated with a good immunotherapeutic response [4].

In T cells, FMNL1 contributes to efficient migration by promoting deformation of the rigid T cell nucleus in confined environments [5]. In membranous nephropathy and other glomerular diseases, anti-FMNL1 IgG4 antibodies are found, which may be related to disease progression [8].

In conclusion, FMNL1 is crucial for cytoskeletal remodeling and has significant impacts on cancer progression, immune cell function, and disease processes in various tissues. Studies using gene knockdown and other loss-of-function models have revealed its role in promoting cancer cell migration, invasion, and proliferation, highlighting its potential as a prognostic factor and therapeutic target in multiple cancers.

References:
1. Zhang, Mei-Fang, Li, Qiu-Li, Yang, Yu-Feng, Cao, Yun, Zhang, Chris Zhiyi. 2020. FMNL1 Exhibits Pro-Metastatic Activity via CXCR2 in Clear Cell Renal Cell Carcinoma. In Frontiers in oncology, 10, 564614. doi:10.3389/fonc.2020.564614. https://pubmed.ncbi.nlm.nih.gov/33324547/
2. Chen, Wen-Hui, Cai, Mu-Yan, Zhang, Jia-Xing, Qian, Chao-Nan, Xie, Dan. 2018. FMNL1 mediates nasopharyngeal carcinoma cell aggressiveness by epigenetically upregulating MTA1. In Oncogene, 37, 6243-6258. doi:10.1038/s41388-018-0351-8. https://pubmed.ncbi.nlm.nih.gov/30013189/
3. Yang, Xing-Yi, Liao, Jun-Jie, Xue, Wu-Rong. 2019. FMNL1 down-regulation suppresses bone metastasis through reducing TGF-β1 expression in non-small cell lung cancer (NSCLC). In Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 117, 109126. doi:10.1016/j.biopha.2019.109126. https://pubmed.ncbi.nlm.nih.gov/31387165/
4. Lu, Guomin, Wang, Hui, Xu, Rui, Zhan, Qiang, Zhang, Qinglin. 2023. Formin protein FMNL1 is a biomarker for tumor-infiltrating immune cells and associated with well immunotherapeutic response. In Journal of Cancer, 14, 2978-2989. doi:10.7150/jca.86965. https://pubmed.ncbi.nlm.nih.gov/37859818/
5. Sigler, Ashton L, Thompson, Scott B, Ellwood-Digel, Logan, Del Alamo, Juan C, Jacobelli, Jordan. 2024. FMNL1 and mDia1 promote efficient T cell migration through complex environments via distinct mechanisms. In Frontiers in immunology, 15, 1467415. doi:10.3389/fimmu.2024.1467415. https://pubmed.ncbi.nlm.nih.gov/39430739/
6. Higa, Nayuta, Shinsato, Yoshinari, Kamil, Muhammad, Yoshimoto, Koji, Arita, Kazunori. 2019. Formin-like 1 (FMNL1) Is Associated with Glioblastoma Multiforme Mesenchymal Subtype and Independently Predicts Poor Prognosis. In International journal of molecular sciences, 20, . doi:10.3390/ijms20246355. https://pubmed.ncbi.nlm.nih.gov/31861134/
7. Favaro, Patricia, Traina, Fabiola, Machado-Neto, João Agostinho, Ridley, Anne J, Saad, Sara Teresinha Olalla. 2013. FMNL1 promotes proliferation and migration of leukemia cells. In Journal of leukocyte biology, 94, 503-12. doi:10.1189/jlb.0113057. https://pubmed.ncbi.nlm.nih.gov/23801653/
8. Bruschi, Maurizio, Cavalli, Andrea, Moll, Solange, Ghiggeri, Gian Marco, Prunotto, Marco. 2022. Discovery of anti-Formin-like 1 protein (FMNL1) antibodies in membranous nephropathy and other glomerular diseases. In Scientific reports, 12, 13659. doi:10.1038/s41598-022-17696-w. https://pubmed.ncbi.nlm.nih.gov/35953506/
9. Miller, Eric W, Blystone, Scott D. 2019. The carboxy-terminus of the formin FMNL1ɣ bundles actin to potentiate adenocarcinoma migration. In Journal of cellular biochemistry, 120, 14383-14404. doi:10.1002/jcb.28694. https://pubmed.ncbi.nlm.nih.gov/30977161/
10. Mansuri, Naziha, Heuser, Vanina D, Birkman, Eva-Maria, Carpén, Olli, Lehtinen, Laura. 2021. FHOD1 and FMNL1 formin proteins in intestinal gastric cancer: correlation with tumor-infiltrating T lymphocytes and molecular subtypes. In Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 24, 1254-1263. doi:10.1007/s10120-021-01203-7. https://pubmed.ncbi.nlm.nih.gov/34115237/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest